New hope for older breast cancer patients: targeted therapy T-DM1 tested in clinical trial
NCT ID NCT03587740
First seen Dec 15, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This study is for older adults with HER2-positive breast cancer, a type that has too much of a protein called HER2. The trial tests a drug called T-DM1, which combines a targeted antibody with chemotherapy to kill cancer cells. The goal is to see if giving T-DM1 after surgery helps prevent the cancer from coming back. About 111 participants are enrolled in this phase 2 study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135, United States
-
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, 01757, United States
-
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
-
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry, New Hampshire, 03053, United States
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02215, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Rex Cancer Center
Raleigh, North Carolina, 27607, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Stamford Hospital
Stamford, Connecticut, 06904, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.